
|Articles|July 15, 2004
Verteporfin-maker QLT to merge with Atrix
Vancouver, British Columbia-An $855 million deal will unite verteporfin (Visudyne) developer QLT Inc. and Atrix Laboratories Inc. to build QLT's business and accelerate strategic initiatives.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Optigo: Lead anti-VEGF program advancing toward IND-enabling studies
2
AAO 2025: Advancements in laser refractive surgery
3
From then to next: Five decades of transformation in ophthalmology
4
AAO 2025: A study of retinal vasculitis events with intravitreal agents
5


















































.png)


